CR11869A - 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos - Google Patents

7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos

Info

Publication number
CR11869A
CR11869A CR11869A CR11869A CR11869A CR 11869 A CR11869 A CR 11869A CR 11869 A CR11869 A CR 11869A CR 11869 A CR11869 A CR 11869A CR 11869 A CR11869 A CR 11869A
Authority
CR
Costa Rica
Prior art keywords
sulfonilmetilindoles
sulfinilmetil
sulfanilmetil
replaced
same
Prior art date
Application number
CR11869A
Other languages
English (en)
Inventor
Kolkhof Peter
Bruns Astrid
Thede Kai
Schlemmer Karl-Heinz
Hillisch Alexander
Lang Dieter
Gerisch Michael
Goller Andreas
Grosser Rolf
Schmeck Carsten
Woltering Elisabeth
Prien Olaf
Paulsen Holger
Kern Armin
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR11869A publication Critical patent/CR11869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindol, a procedimientos para la preparación de los mismos, al uso de los mismos solos o en combinaciones para el tratamiento y/o la prevención de enfermedades, y al uso de los mismos para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente para el tratamiento y/o la prevención de enfermedades cardiovasculares.
CR11869A 2008-06-25 2010-12-23 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos CR11869A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008030207A DE102008030207A1 (de) 2008-06-25 2008-06-25 Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung

Publications (1)

Publication Number Publication Date
CR11869A true CR11869A (es) 2011-05-10

Family

ID=41017186

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11869A CR11869A (es) 2008-06-25 2010-12-23 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos

Country Status (24)

Country Link
US (2) US20110201564A1 (es)
EP (1) EP2300423A1 (es)
JP (1) JP2011525504A (es)
KR (1) KR20110023895A (es)
CN (1) CN102131776A (es)
AR (1) AR072202A1 (es)
AU (1) AU2009262582A1 (es)
BR (1) BRPI0915405A2 (es)
CA (1) CA2729048A1 (es)
CL (1) CL2010001508A1 (es)
CO (1) CO6321237A2 (es)
CR (1) CR11869A (es)
DE (1) DE102008030207A1 (es)
DO (1) DOP2010000400A (es)
EC (1) ECSP10010711A (es)
IL (1) IL209718A0 (es)
MA (1) MA32416B1 (es)
MX (1) MX2010014447A (es)
PE (1) PE20110331A1 (es)
RU (1) RU2011102472A (es)
SV (1) SV2010003773A (es)
TW (1) TW201012800A (es)
UY (1) UY31903A (es)
WO (1) WO2009156072A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137220A1 (en) * 2010-04-28 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule neuropeptide s antagonists for the treatment of addictive disorders, mood, anxiety and sleep disorders
CA2824344A1 (en) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
DE102011015126B4 (de) * 2011-03-25 2014-09-25 Airbus Operations Gmbh Flugzeugheckbereich mit einem in dem Flugzeugheckbereich installierten Kühlsystem
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN111039873B (zh) * 2019-12-20 2022-03-15 河北美荷药业有限公司 一种芬苯达唑亚砜的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2778819A (en) 1950-08-21 1957-01-22 Bayer Ag 1-alkoxy-3 imino-isoindolenine derivatives
NL82464C (es) 1952-01-05
US2765320A (en) 1954-09-03 1956-10-02 Pittsburgh Plate Glass Co Preparation of 2, 3-dimethylindole
KR920701152A (ko) 1988-11-14 1992-08-11 로버트 에이. 아미테이지 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
US5808064A (en) 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
AU4053497A (en) 1996-08-13 1998-03-06 Merck & Co., Inc. Palladium catalyzed indolization
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0406883A (pt) 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
US7728150B2 (en) 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
ES2340180T3 (es) 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
JPWO2007040166A1 (ja) 2005-09-30 2009-04-16 大日本住友製薬株式会社 新規な縮合ピロール誘導体
WO2007062994A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Methods for synthesis of 3-amino-1-arylpropyl indoles
US7960544B2 (en) 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
WO2008157740A2 (en) 2007-06-20 2008-12-24 Ironwood Pharmaceuticals, Inc. Faah inhibitors

Also Published As

Publication number Publication date
KR20110023895A (ko) 2011-03-08
WO2009156072A1 (de) 2009-12-30
BRPI0915405A2 (pt) 2015-11-03
MA32416B1 (fr) 2011-06-01
RU2011102472A (ru) 2012-07-27
US20100105744A1 (en) 2010-04-29
CA2729048A1 (en) 2009-12-30
PE20110331A1 (es) 2011-06-22
CL2010001508A1 (es) 2011-05-06
AU2009262582A1 (en) 2009-12-30
SV2010003773A (es) 2011-08-29
AR072202A1 (es) 2010-08-11
CO6321237A2 (es) 2011-09-20
US20110201564A1 (en) 2011-08-18
ECSP10010711A (es) 2011-01-31
IL209718A0 (en) 2011-02-28
CN102131776A (zh) 2011-07-20
EP2300423A1 (de) 2011-03-30
US8063234B2 (en) 2011-11-22
JP2011525504A (ja) 2011-09-22
MX2010014447A (es) 2011-01-21
UY31903A (es) 2010-01-29
TW201012800A (en) 2010-04-01
DE102008030207A1 (de) 2009-12-31
DOP2010000400A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY31765A (es) Dihidropirazolonas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
UY31922A (es) Compuestos
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CR20110527A (es) Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU23951B1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CR10449A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2010000899A1 (es) N1-bencil-n8-hidroxi octanodiamida; composicion farmaceutica que comprende a dicho compuesto; combinacion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de tumores.(divisional de la solicitud 1247-04).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)